Cyrus Biotechnology Exhibits at the PEGS Protein Engineering Summit in Boston, April 8th – 11th

March 26, 2019

SEATTLE, March 26, 2019 — Cyrus Biotechnology, Inc., a biotechnology software company offering advanced protein modeling and design tools to the Biopharmaceutical, Synthetic Biology, Chemical, and Consumer Products industries is pleased to announce its participation in the 15th Annual PEGS Boston Protein Engineering Summit in Boston, from April 8th through April 11th.

Dr. David Pearlman, Senior Fellow and Director of Customer Experience at Cyrus Bio, and Rosario Caltabiano, Executive VP of Sales, will attend the conference and discuss the latest advances in in silico protein engineering at booth 539 in the Boston Seaport World Trade Center Exhibit Hall.

Cyrus Biotechnology offers commercial tools based on the well-known Rosetta protein design package. The company is a spin out of David Baker’s laboratory at the University of Washington, established to make these tools easier to deploy and use. Cyrus has implemented the Rosetta platform with an easy to use interface on a computing cloud, resulting in high reliability software with high performance, usability and security. Cyrus Bench® software, and the underlying Rosetta software package, are already leveraged by many global pharmaceutical organizations, and Cyrus customers can apply the most advanced and validated in silico protein engineering science through an intuitive user interface for:

  • Protein Structure Prediction (best overall performance at CASP and CAMEO)
  • Antibody Structure Prediction from Sequence
  • Protein Stabilization
  • Computational Affinity Maturation (Interface Design)
  • Fast Free Energy Calculations
  • Prediction of Immunogenic Epitopes
  • Removal of Identified Liabilities
  • Protein Structure Optimization and Design
  • Antibody Engineering
  • Antigen Design
  • Enzyme Design and optimization

About Cyrus Biotechnology Inc.

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering Cyrus Bench®, a Software-as-a-Service (SaaS) platform for protein modeling and design capabilities to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus Bench® is based on the Rosetta software from the laboratory of Prof. David Baker at the University of Washington, the most powerful protein engineering software available. Cyrus customers include 10 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.

Home

Cyrus Biotechnology Chief Science Officer Yifan Song to Speak at BAGIM – Boston Area Group for Informatics and Modeling

SEATTLE, WA March 11, 2019 — Cyrus Biotechnology, Inc., a Seattle-based biotech software company commercializing the advanced protein design platform Rosetta announced today that Dr Yifan Song, Cyrus Bio Chief Scientific Officer, will speak at an upcoming meeting of the Boston Area Group for Informatics and Modeling (BAGIM).

Topic: Got Structure? State-of-the-art protein structure prediction with homology modeling

Date: Thursday, March 14th, 2019

Time: 6:00 PM EDT

Venue: Shire – 125 Binney St, Cambridge, MA 02142

Event on Meetup: https://www.meetup.com/Boston-Area-Group-for-Informatics-and-Modeling/events/259399520/

Abstract:

Most computational methods that can be applied during drug discovery require a protein structure. Ideally, such structures are derived from experimental approaches such as X-ray, EM or NMR. However, frequently, an experimental structure of the specific protein of interest is not available. In such a case we turn to homology modeling.

The state-of-the-art for homology model prediction has progressed tremendously over the past two decades. Whereas useful HM models were initially only available in cases where a high-similarity homolog was available in the PDB, it is now often possible to predict such models even when the best homologs have only 15-25% similarity to the sequence whose structure is being predicted. The dramatic improvement in what is possible with HM is due to several factors, including: adoption of methods that can identify suitable low similarity templates on the basis of Markov Models, familial and other deep analysis of sequence space; the ability to incorporate multiple low-similarity templates to broadly span a target sequence; powerful approaches to model building that can handle missing structure due to lack of template, insertions and deletions; and the availability of massive compute power through processor clusters and parallelization. In many cases, the HM models that can be generated are so good—not only in terms of backbone trace, but also in such fine details as hydrogen bonding network, salt bridges, disulphide bonds, etc.—that they are suitable for downstream modeling methods.

We will present the history of HM approaches, culminating in a description of the state-of-the-art Rosetta HM workflow.


For more information on Cyrus Bench, click here.

About BAGIM (Boston Area Group for Informatics and Modeling)
BAGIM is an active community of Boston area scientists bringing together people from diverse fields of modeling and informatics to impact life and health sciences. BAGIM strives to create a forum for great scientific discussions covering a wide range of topics including data management, visualization, computational chemistry, drug discovery, protein structure, molecular modeling, structure-based drug design, data mining, software tools, and the sharing of goals and experiences. Our community is made up of participants from academia, government, and/or industry whose goal is to engage in the discussion of science involving a synthesis of theory and technology. Discussions sponsored by BAGIM are targeted to the needs and interests of informatics scientists, computational chemists, medicinal chemists, and statisticians. BAGIM also provides opportunities for networking within these disciplines as well as an arena for the dissemination of information of specific interest to the membership.
http://bagim.org

About Cyrus
Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering Cyrus Bench®, a SaaS platform for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus Bench® is based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington, the most powerful protein engineering software available. Cyrus customers include 10 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.
https://www.cyrusbio.com/

Cyrus Contact – Lucas Nivon

lucas@cyrusbio.com

206-258-6561

Cyrus Biotechnology Announces Release of Antibody Structure Prediction Software for Biologics Drug Development and Discovery

SEATTLE, WA March 5, 2019 — Cyrus Biotechnology, Inc., a Seattle-based biotech software company commercializing Rosetta, an advanced protein design platform, announced today the release of a novel Antibody Structure Prediction Software tool as part of its Cyrus Bench® platform.

“Antibodies make up the majority of Biologics, and now Cyrus users can model new antibodies in Bench®” said Cyrus CEO Dr. Lucas Nivon. “Antibody modeling in Rosetta was pioneered by a number of laboratories, especially that of Dr. Jeffrey Gray at Johns Hopkins University, but those methods have remained difficult to access. Our new offering makes these applications significantly more robust and easier to use, so both laboratory biochemists and antibody engineers can rely on them.”

Rosetta software is the world leader in protein modeling and design. Now, the most up-to-date protocols in Rosetta for antibody modeling are available in Bench®, facilitating work on a wider variety of common monoclonal antibody engineering problems. When combined with Cyrus’ protein modeling tools for predicting how protein mutations affect stability and affinity, these antibody prediction tools make possible complex workflows for improving efficacy or reducing potential liabilities in candidate antibody biologics.

The Rosetta antibody tools, successfully validated in the Antibody Modeling Assessment (AMA-II), have now been extended to accept a broader range of inputs without user intervention. Cyrus’ implementation uses machine learning to improve the accuracy of the antibody structure prediction workflow.

The new antibody homology modeling software is now available to subscribers to Cyrus Bench® and to new customers who subscribe to the Cyrus Bench® suite of tools.

https://www.businesswire.com/news/home/20190305005035/en/Cyrus-Biotechnology-Announces-Release-Antibody-Structure-Prediction

About Cyrus

Cyrus Biotechnology, Inc. is a privately-held biotechnology software company offering Cyrus Bench®, a SaaS platform for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus Bench® is based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington, the most powerful protein engineering software available. Cyrus customers include 10 of the top 20 Global Pharmaceutical firms and is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund.

Cyrus Contact – Lucas Nivon

lucas@cyrusbio.com

206-258-6561